

Table 4: Hazard ratio for Intraocular Pressure <5mmHg, sustained for at least 30 days

		Univariate n=6,785 events=126			Multivariate** n=6,540 event=97		
		Events/ At Risk	Hazard Ratio (95% Confidence Interval)	p- value	Events/ At Risk	Hazard Ratio (95% Confidence Interval)	p- value
Age	<18	45/973	4.97 (2.58 - 9.57)	<.001	36/933	2.92 (1.20 - 7.10)	0.15
	18-25	22/897	2.50 (1.21 - 5.15)		19/878	2.27 (0.98 - 5.27)	
	26-35	15/1483	Reference		12/1458	Reference	
	36-45	15/1300	1.19 (0.53 - 2.65)		11/1275	0.99 (0.40 - 2.43)	
	46-55	13/983	1.39 (0.63 - 3.08)		9/963	1.00 (0.35 - 2.85)	
	56-65	6/556	1.14 (0.39 - 3.35)		5/548	0.79 (0.22 - 2.82)	
	>65	7/497	1.87 (0.69 - 5.07)		5/485	0.84 (0.24 - 2.97)	
Gender	Male	34/2388	Reference	0.12	23/2305	Reference	0.49
	Female	92/4397	1.45 (0.91 - 2.30)		74/4235	1.22 (0.70 - 2.14)	
Race	White	73/4755	Reference	0.002	55/4629	Reference	0.74
	African-derived	42/1208	2.22 (1.42 - 3.46)		32/1148	1.25 (0.71 - 2.22)	
	Other	11/822	1.10 (0.52 - 2.30)		10/763	1.03 (0.49 - 2.14)	
Contralateral uveitis	No	8/1170	Reference	0.02	8/1144	Reference	0.41
	Yes	118/5615	2.35 (1.14 - 4.87)		89/5396	1.39 (0.63 - 3.07)	
Hypertension	No	86/5547	Reference	0.006	70/5351	Reference	0.052
	Yes	40/1238	1.89 (1.20 - 2.97)		27/1189	2.04 (0.99 - 4.20)	
Diabetes	No	121/6398	Reference	0.37	95/6169	Reference	0.16
	Yes	5/387	0.66 (0.26 - 1.65)		2/371	0.34 (0.08 - 1.52)	
Systemic Diseases	Any†	57/1846	1.80 (1.20 - 2.72)	0.005	43/1775	0.79 (0.42 - 1.49)	0.46
	HLA-B27 and/or spondyloarthritis	16/801	1.05 (0.58 - 1.88)	0.88	12/784	1.43 (0.61 - 3.32)	0.41
	Juvenile idiopathic arthritis	33/329	6.13 (3.83 - 9.81)	<.001	25/297	2.04 (0.79 - 5.31)	0.14
	Sarcoidosis	14/576	1.05 (0.53 - 2.07)	0.88	11/555	0.97 (0.38 - 2.48)	0.96
Type of Uveitis	Anterior Uveitis	74/3609	Reference	<.001	61/3459	Reference	<.001
	Intermediate Uveitis	6/1197	0.20 (0.07 - 0.58)		4/1169	0.17 (0.05 - 0.56)	
	Posterior Uveitis	3/1112	0.10 (0.03 - 0.31)		2/1087	0.11 (0.03 - 0.45)	
	Panuveitis	43/867	1.93 (1.24 - 3.01)		30/825	1.25 (0.67 - 2.35)	
Duration of uveitis at presentation	<6 months	18/2749	Reference	<.001	10/2613	Reference	0.002
	6 months to 2 years	15/1401	1.46 (0.67 - 3.17)		14/1382	1.52 (0.59 - 3.94)	
	2 to 5 years	27/1134	3.36 (1.68 - 6.69)		26/1112	4.53 (1.94 - 10.61)	
	Greater than 5 years	66/1501	6.13 (3.33 - 11.26)		47/1433	3.08 (1.30 - 7.31)	
Prior Cataract Surgery by Type	None	32/*	Reference	<.001	19/*	Reference	<.001
	Phacoemulsification	13/*	4.21 (2.15 - 8.27)		13/*	4.87 (2.25 - 10.55)	
	Extracapsular cataract surgery	17/*	8.00 (4.34 - 14.73)		16/*	6.50 (3.14 - 13.45)	
	Intracapsular cataract surgery	11/*	22.20 (9.32 -		8/*	12.19 (3.78 -	

			52.89)			39.30)		
	Pars plana lensectomy	19/*	25.63 (13.86 - 47.40)		18/*	8.51 (3.12 - 23.21)		
	Unknown	34/*	13.98 (8.10 - 24.13)		23/*	7.28 (3.31 - 16.00)		
Prior Pars Plana Vitrectomy	No	89/*	Reference	<.001	63/*	Reference	0.008	
	Yes	37/*	5.58 (3.61 - 8.62)		34/*	2.03 (1.21 - 3.42)		
Prior Retinal Detachment Surgery	No	118/*	Reference	<.001	91/*	Reference	0.88	
	Yes	8/*	4.87 (2.24 - 10.59)		6/*	0.92 (0.29 - 2.89)		
Signs of Inflammatory Activity	Anterior chamber cells	Quiet	72/*	Reference	0.03	58/*	Reference	0.45
		0.5+	26/*	1.94 (1.20 - 3.14)		19/*	0.86 (0.46 - 1.58)	
		1+	14/*	1.76 (0.93 - 3.35)		13/*	1.24 (0.63 - 2.46)	
		2+	4/*	0.78 (0.28 - 2.14)		3/*	0.31 (0.08 - 1.14)	
		3+ or worse	5/*	1.87 (0.76 - 4.63)		4/*	0.97 (0.32 - 2.94)	
	Vitreous cells	Quiet	74/*	Reference	<.001	63/*	Reference	0.005
		0.5+	11/*	1.02 (0.54 - 1.92)		10/*	0.97 (0.46 - 2.04)	
		1+	8/*	0.80 (0.38 - 1.69)		7/*	0.72 (0.27 - 1.90)	
		2+	7/*	1.23 (0.55 - 2.75)		7/*	1.61 (0.65 - 3.94)	
		3+ or worse	10/*	6.07 (2.99 - 12.32)		6/*	4.73 (2.08 - 10.76)	
	Vitreous haze	Quiet	75/*	Reference	<.001	64/*	Reference	0.006
		1+	20/*	2.97 (1.81 - 4.86)		19/*	2.48 (1.32 - 4.67)	
		2+	8/*	4.65 (2.05 - 10.56)		8/*	3.87 (1.60 - 9.32)	
		3+ or worse	5/*	6.69 (2.29 - 19.58)		2/*	1.32 (0.26 - 6.78)	
	Keratic precipitates	No	104/*	Reference	0.18	80/*	Reference	0.22
		Yes	14/*	1.52 (0.83 - 2.78)		13/*	1.60 (0.75 - 3.42)	
	Structural complications	Any†	85/*	2.65 (1.77 - 3.96)	<.001	70/*	1.78 (1.06 - 2.99)	0.03
		Band keratopathy	38/*	12.24 (7.90 - 18.98)	<.001	29/*	3.14 (1.42 - 6.98)	0.005
		Peripheral anterior synechia	7/*	3.38 (1.55 - 7.37)	0.002	5/*	1.16 (0.42 - 3.14)	0.78
		Posterior synechia	31/*	1.88 (1.22 - 2.89)	0.005	23/*	2.05 (1.21 - 3.45)	0.007
Exudative detachment		9/*	14.15 (6.77 - 29.55)	<.001	9/*	5.25 (1.86 - 14.80)	0.002	

† Any systemic disease includes those in the table as well as Behçet's disease. Any structural complication includes those in the table as well as choroidal neovascularization, epiretinal membrane, exudative detachment, macular edema and retinal neovascularization

* The number at risk for time-varying characteristics changes over followup, and is therefore not reported as a number of patients

** Adjusting for age, race, hypertension, juvenile idiopathic arthritis, systemic diseases†, type of uveitis, presence of contralateral uveitis, duration of uveitis at presentation, prior cataract surgery by type, prior pars plana vitrectomy, prior retinal detachment surgery, anterior chamber cells and presence of exudative retinal detachment. However, ‡ Vitreous cells and haze are never adjusted by anterior chamber cells

§ Hyperlipidemia, smoking status, epiretinal membrane, and macular edema were studied but are not included in the table because they were never found to be significant at $p < 0.10$. Retinal vascular sheathing, presence of active lesions in choroid/retina, snowballs, snowbanking, Behçes Disease, choroidal neovascularization and retinal neovascularization are excluded from the table because eyes with these characteristics had fewer than 5 hypotony events, and there was no suggestion of a protective pattern.